Question 1

What is Crinetics Pharmaceuticals, Inc.'s WACC?

Accepted Answer

Crinetics Pharmaceuticals, Inc. (CRNX) has a Weighted Average Cost of Capital (WACC) of 9.12%. This is calculated using a Cost of Equity of 9.12% (via CAPM with a beta of 1.15) and a pre-tax Cost of Debt of 5.00%, with an equity weight of 100.00% in the capital structure.

Question 2

Is Crinetics Pharmaceuticals, Inc.'s WACC high or low?

Accepted Answer

Crinetics Pharmaceuticals, Inc.'s WACC of 9.12% falls within the typical 8-12% range for mid-cap growth companies. WACC is used as the discount rate in DCF valuations — a lower WACC results in higher present values of future cash flows.

Question 3

How is Crinetics Pharmaceuticals, Inc.'s WACC calculated?

Accepted Answer

Crinetics Pharmaceuticals, Inc.'s WACC is calculated using the formula: WACC = (E/V × Re) + (D/V × Rd × (1-T)). The Cost of Equity (Re) of 9.12% is derived from the CAPM model using a beta of 1.15. The pre-tax Cost of Debt (Rd) is 5.00%. The capital structure is 100.00% equity and 0.00% debt.

Crinetics Pharmaceuticals, Inc. (CRNX) — WACC 分析

WACC 构成

解读

Crinetics Pharmaceuticals, Inc.（CRNX）WACC：9.12%

WACC计算器

Crinetics Pharmaceuticals, Inc.（CRNX） WACC 解读

CRNX 公司分析

CRNX DCF 估值

继续做同行对比